Download PDF
TumorDiagnostik & Therapie 2020; 41(08): 521-526
DOI: 10.1055/a-1211-0859
Schwerpunkt Kopf-Hals-Tumoren

Moderne Therapiekonzepte bei Kopf-Hals-Tumoren

Henrike Barbara Zech
,
Chia-Jung Busch
› Further Information
Also available at
    Permissions and Reprints

Die aktuellen Standards in der Therapie von Kopf-Hals-Karzinomen unterliegen einem deutlichen Wandel. Dieser Beitrag hebt beispielhaft Änderungen in der systemischen Therapie in den letzten Jahren hervor und diskutiert mögliche zukünftige Neuerungen auf der Grundlage aktueller wissenschaftlicher Studien.

Publication History

Article published online:
07 October 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Siegel RL, Miller KD, Jemal A. Cancer Statistics 2017. CA Cancer J Clin 2017; 67: 7-30
    CrossrefPubMedGoogle Scholar
  • 2 Vermorken JB, Mesia R, Rivera F. et al Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127
    CrossrefPubMedGoogle Scholar
  • 3 Ferris RL, Blumenschein Jr G, Fayette J. et al Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016; 375: 1856-1867
    CrossrefPubMedGoogle Scholar
  • 4 Cohen EEW, Soulieres D, Le Tourneau C. et al Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393: 156-167
    CrossrefPubMedGoogle Scholar
  • 5 Burtness B, Harrington KJ, Greil R. et al Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394: 1915-1928
    CrossrefPubMedGoogle Scholar
  • 6 Fuchs H, Pammer J, Minichsdorfer C. et al Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer. Med Oncol 2018; 35: 32
    CrossrefPubMedGoogle Scholar
  • 7 Guigay J, Fayette J, Mesia R. et al TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). ASCO Virtual Scientific Program 2020: 6520
    PubMedGoogle Scholar
  • 8 Li W, Wildsmith S, Ye J. et al Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. ASCO Virtual Scientific Program 2020: 6511
    PubMedGoogle Scholar
  • 9 Starzer AM, Heller G, Tomasich E. et al DNA methylation profiling in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors. ASCO Virtual Scientific Program 2020: e18527
    PubMedGoogle Scholar
  • 10 Gavrielatou N, Doumas S, Economopoulou P. et al Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 2020; 84: 101977
    CrossrefPubMedGoogle Scholar
  • 11 Haider SP, Burtness B, Yarbrough WG. et al Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. Cancers of the Head & Neck 2020; 5: 6
    CrossrefPubMedGoogle Scholar
  • 12 Vellanki PJ, Marur S, Bandaru P. et al Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). ASCO Virtual Scientific Program 2020: 6509
    PubMedGoogle Scholar
  • 13 Cohen EEW, Nabell L, Wong DJ. et al Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). ASCO Annual Meeting 2019: 6039
    PubMedGoogle Scholar
  • 14 Felip E, Doger B, Majem M. et al Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab. ASCO Virtual Scientific Program 2020: 3100
    PubMedGoogle Scholar
  • 15 Angevin E, Groenland SL, Lim AML. et al Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC). ASCO Virtual Scientific Program 2020: 6517
    PubMedGoogle Scholar
  • 16 Chung CH, Bonomi MR, Steuer CE. et al Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study. ASCO Virtual Scientific Program 2020: 6515
    PubMedGoogle Scholar
  • 17 Cohen RB, Bauman JR, Salas S. et al Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. ASCO Virtual Scientific Program 2020: 6516
    PubMedGoogle Scholar
  • 18 Taylor MH, Lee CH, Makker V. et al Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol 2020; 38: 1154-1163
    CrossrefPubMedGoogle Scholar
  • 19 Zehir A, Benayed R, Shah RH. et al Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017; 23: 703-713
    CrossrefPubMedGoogle Scholar
  • 20 Drilon A, Laetsch TW, Kummar S. et al Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-739
    CrossrefPubMedGoogle Scholar
  • 21 Li BT, Shen R, Offin M. et al Ado-trastuzumab emtansine in patients with HER2/amplified salivary gland cancers (SGCs): Results from a phase II basket trial. ASCO Annual Meeting 2019; 6001
    PubMedGoogle Scholar
  • 22 Tchekmedyian V, Sherman EJ, Dunn L. et al Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma. J Clin Oncol 2019; 37: 1529-1537
    CrossrefPubMedGoogle Scholar
  • 23 Keam B, Kang EJ, Ahn MJ. et al Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. ASCO Virtual Scientific Program 2020: 6503
    PubMedGoogle Scholar
  • 24 Ho AL, Hanna GJ, Scholz CR. et al Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations. ASCO Virtual Scientific Program 2020: 6504
    PubMedGoogle Scholar
  • 25 Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576-582
    CrossrefPubMedGoogle Scholar
  • 26 Kiyota N, Tahara M, Fujii H. et al Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). ASCO Virtual Scientific Program: 2020: 6502
    PubMedGoogle Scholar
  • 27 Ferris RL, Flamand Y, Weinstein GS. et al Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). ASCO Virtual Scientific Program 2020: 6500
    PubMedGoogle Scholar
  • 28 Mehanna H, Rischin D, Wong SJ. et al De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. J Clin Oncol 2020; 38: 2552-2557
    CrossrefPubMedGoogle Scholar
  • 29 Noronha V. The three pillars of systemic therapy. Vortrag und Diskussion. Im Internet: meetinglibrary.asco.org/record/178133/video ASCO Annual Meeting 2019. Stand: 29.07.2020
    PubMedGoogle Scholar
  • 30 Kao HF, Lou PJ. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. Head Neck 2019; 41 (Suppl. 01) 4-18
    CrossrefPubMedGoogle Scholar